دورية أكاديمية
Topical cyclosporin A 0.05% eye drops for management of symptomatic acquired punctal stenosis: a prospective, controlled clinical study.
| العنوان: | Topical cyclosporin A 0.05% eye drops for management of symptomatic acquired punctal stenosis: a prospective, controlled clinical study. |
|---|---|
| المؤلفون: | Nassief M; Department of Ophthalmology, Faculty of Medicine, Tanta University, Tanta, Egypt., Lotfy NM; Department of Ophthalmology, Faculty of Medicine, Cairo University, Cairo, Egypt. |
| المصدر: | Orbit (Amsterdam, Netherlands) [Orbit] 2024 Apr; Vol. 43 (2), pp. 190-195. Date of Electronic Publication: 2023 Jul 18. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8301221 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-5108 (Electronic) Linking ISSN: 01676830 NLM ISO Abbreviation: Orbit Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: London : Informa Healthcare Original Publication: Amsterdam : Aeolus Press, [1982- |
| مواضيع طبية MeSH: | Lacrimal Apparatus Diseases* , Eyelid Diseases* , Lacrimal Apparatus* , Lacrimal Duct Obstruction*/drug therapy, Humans ; Cyclosporine ; Constriction, Pathologic ; Prospective Studies ; Stents |
| مستخلص: | Purpose: To study the efficacy of cyclosporin 0.05% eye drops in the management of grade 1 and 2 acquired punctal stenosis and to compare the results with the clinical outcomes of mini-Monoka insertion. Methods: A prospective, controlled, interventional clinical study includes all patients (16 years and older) with symptomatic epiphora and diagnosed with grade 1 or grade 2 acquired punctal stenosis. All patients undergo punctal dilatation, canalicular probing, and nasolacrimal duct irrigation. Afterwards, patients are divided into two groups: Group A: patients receive only medical treatment in the form of topical 0.05% cyclosporin (Restasis®, Allergan Inc.) twice daily for 6 months. Group B: patients receive mini-Monoka stent insertion in the lower canaliculus for 6 weeks. Outcome measures are changes in Munk scoring, grading of the punctum, and functional and anatomical success. Functional success is defined as Munk score 0 to 1 and FDDT grade 0-2. Anatomical success is defined as grade 3 punctum. Results: Forty-two patients are included in the study, with 21 patients in each group. There were no significant differences in the Munk score between the two groups before treatment; however, group B had a significantly higher mean rank at 6 months after treatment. After treatment, the punctal size was significantly larger in group B at 4 weeks and 3 months. However, no significant difference in punctal size was detected at 6 months after treatment between the two groups. Conclusion: Application of cyclosporin 0.05% eye drops is a simple and efficient non-interventional method in the management of grade 1 and 2 acquired punctal stenosis. |
| فهرسة مساهمة: | Keywords: Cyclosporin; Restasis; mini-Monoka; punctal stenosis |
| المشرفين على المادة: | 83HN0GTJ6D (Cyclosporine) |
| تواريخ الأحداث: | Date Created: 20230718 Date Completed: 20240401 Latest Revision: 20240401 |
| رمز التحديث: | 20240401 |
| DOI: | 10.1080/01676830.2023.2232028 |
| PMID: | 37463348 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher | تدمد: | 1744-5108 |
|---|---|
| DOI: | 10.1080/01676830.2023.2232028 |